AL 24 2A1Alternative Names: AL-24-2A1
Latest Information Update: 13 Jul 2016
At a glance
- Originator Allosterix Pharma
- Class Small molecules
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Rheumatoid arthritis
Most Recent Events
- 13 Jul 2016 Early research in Rheumatoid arthritis in Israel (PO)